Flu-like and Other Systemic Drug Reactions among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study

Timothy R. Sterling, Ruth N. Moro, Andrey S. Borisov, Elizabeth Phillips, Gillian Shepherd, Newton Franklin Adkinson, Stephen Weis, Christine Ho, Margarita Elsa Villarino, N. Franklin Adkinson, Jacques Grosset, Judith Hackman, Robert G. Hamilton, M. Elsa Villarino, Nong Shang, Fred Gordin, Awal Khan, Carol Dukes Hamilton, Dick Menzies, Amy KerriganC. Robert Horsburgh, Richard E. Chaisson, George McSherry, Bert Arevalo, Andrew Vernon, David G. Kleinbaum, Charles Heilig, Kimberly Fryer, Isabelle Sanchez, Suet K. Lam, Nigel Scott

Research output: Contribution to journalArticle

40 Scopus citations

Abstract

Background. Weekly rifapentine plus isoniazid for 3 months (3HP) is as effective as daily isoniazid for 9 months (9H) for latent tuberculosis infection in high-risk persons, but there have been reports of possible flu-like syndrome. Methods. We identified clinically significant systemic drug reactions (SDR) and evaluated risk factors in patients who did not complete treatment in the PREVENT Tuberculosis study. Results. Among 7552 persons who received 1 dose of study drug, 153 had a SDR: 138/3893 (3.5%) with 3HP vs 15/3659 (0.4%) with 9H (P <. 001). In the 3HP arm, 87 (63%) had flu-like syndrome and 23 (17%) had cutaneous reactions; 13/3893 (0.3%) had severe reactions (6 were hypotensive) and 6 reported syncope. Symptoms occurred after a median of 3 doses, and 4 hours after the dose; median time to resolution was 24 hours. There were no deaths. In multivariate logistic regression analysis, factors independently associated with SDR included receipt of 3HP (adjusted odds ratio [aOR] 9.4; 95% confidence interval [CI], 5.5, 16.2), white non-Hispanic race/ethnicity (aOR 3.3; 95% CI, 2.3, 4.7), female sex (aOR 2.0; 95% CI, 1.4, 2.9), age 35 years (aOR 2.0; 95% CI, 1.4, 2.9), and lower body mass index (body mass index [BMI]; P =. 009). In a separate multivariate analysis among persons who received 3HP, severe SDR were associated with white non-Hispanic race/ethnicity (aOR 5.4; 95% CI, 1.8, 16.3), and receipt of concomitant non-study medications (aOR 5.9; 95% CI, 1.3, 27.1). Conclusions. SDR were more common with 3HP, and mostly flu-like. Persons of white race, female sex, older age, and lower BMI were at increased risk. Severe reactions were rare and associated with 3HP, concomitant medication, and white race. The underlying mechanism is unclear.

Original languageEnglish
Pages (from-to)527-535
Number of pages9
JournalClinical Infectious Diseases
Volume61
Issue number4
DOIs
StatePublished - 15 Aug 2015

Keywords

  • adverse drug reaction
  • flu-like syndrome
  • isoniazid
  • rifapentine
  • treatment of latent M. tuberculosis infection

Fingerprint Dive into the research topics of 'Flu-like and Other Systemic Drug Reactions among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study'. Together they form a unique fingerprint.

Cite this